M A Lumish,N Tarazona,Y Y Janjigian
M A Lumish
M B Faries,A A E Testori,J E Gershenwald
M B Faries
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆ [0.03%]
EORTC研究小组、澳大利亚胃肠肿瘤研究组(AGITG)、UNICANCER、法国肉瘤研究小组(FSG)、意大利肉瘤研究小组(ISG)及西班牙肉瘤研究小组(GEIS)关于伊马替尼治疗局部胃肠道间质瘤的随机试验最终分析
P G Casali,A Le Cesne,A P Velasco et al.
P G Casali et al.
Background: In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery in localized, high/intermediate-risk gastrointestinal stromal tumors (GIST) patients. Inter...
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ [0.03%]
肺和胸腺类癌瘤：诊断、治疗及随访欧洲肿瘤医学学会临床实践指南
E Baudin,M Caplin,R Garcia-Carbonero et al.
E Baudin et al.
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research [0.03%]
欧洲肿瘤内科学会RET融合和突变检测规范的专家共识声明
C Belli,F Penault-Llorca,M Ladanyi et al.
C Belli et al.
Aberrant activation of RET is a critical driver of growth and proliferation in diverse solid tumours. Multikinase inhibitors (MKIs) showing anti-RET activities have been tested in RET-altered tumours with variable results. The low target sp...
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆ [0.03%]
Niraparib维持治疗铂敏感复发性卵巢癌个体化起始剂量的随机双盲安慰剂对照III期试验（NORA）
X H Wu,J Q Zhu,R T Yin et al.
X H Wu et al.
Background: This study evaluated maintenance treatment with niraparib, a potent inhibitor of poly(ADP-ribose) polymerase 1/2, in patients with platinum-sensitive recurrent ovarian cancer. ...
Corrigendum to 'Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases': Annals of Oncology 2009; 20: 1136-1141 [0.03%]
青年人及成年人骨肉瘤的预后分析(有无肺转移):《肿瘤学年鉴》2009；20：1136-1141发表的文章更正通知
A H Aljubran,A Griffin,M Pintilie et al.
A H Aljubran et al.
Multidisciplinary tumor boards as videoconferences - a new challenge in the COVID-19 era [0.03%]
新冠疫情时代以视频会议形式开展的多学科肿瘤组会是一项新的挑战
M W Gross,H Läubli,D Cordier
M W Gross